Key Clinical Summary: Translating Factor XIa Inhibition Evidence into Practice

This is a micro-learning module summary of a presentation by Dr. Jeffrey L. Saver which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported by an independent education grant from Bayer. This education program is only available to healthcare professionals in the USA.

The primary challenge in secondary stroke prevention is the clinical tradeoff between preventing pathologic thrombosis and maintaining protective hemostasis. Traditional antithrombotics, while effective at reducing ischemic events, inherently increase the risk of cerebral hemorrhage. Emerging evidence suggests that Factor XIa (FXIa) inhibition may "uncouple" these effects, providing a safer therapeutic window for stroke prevention.

Rationale for Targeting Factor XIa

Differential Role: Factor XI plays a minor role in initial hemostatic plug formation but is a major driver of intravascular thrombosis.
Genetic Support: Genetic studies of individuals with Factor XI deficiency show they have a lower incidence of ischemic stroke without a corresponding increase in spontaneous bleeding.
Enhanced Mechanism: In non-cardioembolic stroke, vessel wall injury exposes tissue factor, which activates the coagulation cascade. Adding a FXIa inhibitor to antiplatelet therapy addresses this additional thrombogenic mechanism.

Key Clinical Trial Evidence

Asundexian

PACIFIC-STROKE (Phase 2): This dose-finding study in patients with non-cardioembolic stroke on antiplatelet therapy found that 50 mg of asundexian daily was associated with a 35% reduction in the hazard of recurrent ischemic stroke or TIA compared to placebo. Crucially, there was no significant increase in major bleeding.
OCEANIC-STROKE (Phase 3): Evaluating long-term use of 50 mg asundexian added to single or dual antiplatelet therapy. Initial findings demonstrated a highly statistically significant 25% reduction in ischemic stroke hazard without increasing major bleeding or hemorrhagic stroke.

Milvexian

AXIOMATIC-SSP (Phase 2): This trial showed a potential reduction in symptomatic ischemic stroke when milvexian was added to antiplatelet therapy. Like asundexian, milvexian did not meaningfully increase major bleeding across the doses tested.
LIBREXIA-STROKE (Phase 3): An ongoing large-scale trial (enrolling ~15,000 patients) expected to provide definitive efficacy and safety data by late 2026.

Abelacimab

Mechanism: A monoclonal antibody given by injection that achieves near-complete, month-long Factor XI inhibition with a single dose.
Current Status: While Phase 2 (AZALEA-TIMI 71) showed a massive reduction in bleeding compared to standard anticoagulants in atrial fibrillation, Phase 3 trials (LILAC-TIMI 76) are ongoing to confirm its efficacy in preventing ischemic events.

Clinical Implications and Future Practice

The emerging data supports a shift toward Triple Anti-Thrombotic Therapy (TATT)—the strategy of adding a FXIa inhibitor to initial dual antiplatelet therapy (DAPT). Trial results indicate that this approach can significantly reduce recurrent ischemic stroke, myocardial infarction, and vascular death across all major stroke subtypes (large artery, small vessel, or cryptogenic) without compromising patient safety through increased hemorrhage.

Content is accurate as of the date of release